ADULT NON-HODGKIN'S LYMPHOMA (CLINICAL CASE)
Main Article Content
Abstract
Diffuse B-large cell lymphoma (DVCL) belongs to the group of orphan diseases, is one of the variants of aggressive non-Hodgkin lymphomas of adults. In the Russian Federation, DVCL accounts for approximately 30-40 % of all malignant lymphomas, in 2020, approximately 10112 newly diagnosed malignant lymphomas were registered in Russia, of which about 3000 new cases of DVCL. Over the past two decades, the most common treatment regimen for DVCL, regardless of the morphological variant, immunohistochemical profile and clinical subtype of the tumor, remains the immunochemotherapy regimen with the use of rituximab and its various modifications. Attempts to improve the regime in a wide population of DVKL for 20 years have not shown positive results.
This article describes a rare clinical case of DVCL with the use of polatuzumab vedotin, the first in its class conjugate of a monoclonal antibody to CD79b and a cytotoxic agent.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases /ed. I.V. Poddubnaya, V.G. Savchenko. Moscow, 2018. 470 p. Russian (Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний /под ред. И.В. Поддубной, В.Г. Савченко. Москва, 2018. 470 c.) https://rusoncohem.ru/wp-content/uploads/2019/02/Rossii-skie-klinicheskie-rekomendatsii-po-diagnostike-i-lecheniyu-limfoproliferativnyh-zabolevanii-2018.pdf
Malignant neoplasms in Russia in 2020 (morbidity and mortality) / ed. HELL. Kaprina, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Herzen, 2021. 252 p. Russian (Злокачественные новообразования в России в 2020 г. (заболеваемость и смертность) /под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена, 2021. 252 с.)
Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al.; PHOENIX investigators. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019; 37(15): 1285-1295. DOI: 10.1200/JCO.18.02403
Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 384(9): 842-858. DOI: 10.1056/NEJMra2027612
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 386(4): 351-363. DOI: 10.1056/NEJMoa2115304
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14): 987-994. DOI: 10.1056/NEJM199309303291402
Herrera A, McCord R, Kimes P, Jardin F, Lenz G, Trneny M, et al. Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study. Blood. 2022; 140(Supplement 1): 1297-1300. DOI: 10.1182/blood-2022-157559
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022; 386(4): 351-363. DOI: 10.1056/NEJMoa2115304
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16): 1800-1808. DOI: 10.1182/blood-2017-03-769620
Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022; 6(2): 533-543. DOI: 10.1182/bloodadvances.2021005794
Sehn LH, Flowers C, McMillan A, Morschhauser F. Estimation of long-term survival with polatuzumab vedotin plus bendamustine and rituximab for patients with relapsed/refractory diffuse large b-cell lymphoma (r/r dlbcl). Hematol Oncol. 2019; 37(S2): 257-258. DOI:10.1002/hon.66_2630
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020; 38(2): 155-165. DOI: 10.1200/JCO.19.00172
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma. Electronic resource. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-chemoimmunotherapy-regimen-patients-relapsed-or-refractory-diffuse-large-b-cell. Accessed: April 4, 2023
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma. Electronic resource. Available at: https://www.roche.com/media/releases/med-cor-2020-01-21. Accessed: April 4, 2023